Cita APA

Iwai, T., Sugimoto, M., Wakita, D., Yorozu, K., Kurasawa, M., & Yamamoto, K. (2018). Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies. Oncotarget.

Chicago Style Citation

Iwai, Toshiki, Masamichi Sugimoto, Daiko Wakita, Keigo Yorozu, Mitsue Kurasawa, i Kaname Yamamoto. "Topoisomerase I Inhibitor, Irinotecan, Depletes Regulatory T Cells and Up-regulates MHC Class I and PD-L1 Expression, Resulting in a Supra-additive Antitumor Effect When Combined With Anti-PD-L1 Antibodies." Oncotarget 2018.

Cita MLA

Iwai, Toshiki, et al. "Topoisomerase I Inhibitor, Irinotecan, Depletes Regulatory T Cells and Up-regulates MHC Class I and PD-L1 Expression, Resulting in a Supra-additive Antitumor Effect When Combined With Anti-PD-L1 Antibodies." Oncotarget 2018.